Vision is fundamentally bioelectric

Good vision depends on a carefully regulated electrical environment within the retina. The i-LUMEN AMD System® is a bioelectric therapy intended to restore retinal electrophysiology in patients with intermediate to advanced dry AMD.

How it works
The challenge

A growing need

Millions of patients with intermediate to advanced dry AMD face progressive vision loss with limited treatment options. As visual function declines, recognizing faces, reading, driving, and maintaining independence can become increasingly difficult.

By 2029, the intermediate to advanced AMD population is projected to reach 143.6* million globally, underscoring the growing need for new therapeutic approaches.

*Komodo Health AMD ICD-10 diagnosis coding data

The biological Insight

The electrophysiology of the eye is complex

The Retinal Pigment Epithelium (RPE) is one of the most complex and highly polarized epithelial cell structures in the body. This specialized layer sustains photoreceptors and other retinal cells that enable vision.

Photoreceptors detect light and convert it into electrical signals, while bipolar and ganglion cells process and transmit those signals to the brain.

A healthy RPE maintains a strong transepithelial potential (TEP), an electrical polarity, which can weaken over time due to:

  • Oxidative stress
  • Inflammation
  • Aging RPE cells

i-Lumen Scientific has developed a bioelectric therapy intended to support the restoration of retinal electrophysiology.

Step 1

Repolarizes RPE cells

Proprietary monophasic and biphasic microcurrent delivered through the closed eyelid during an in-office treatment.

Step 2

Restores neurotrophic growth factors produced by RPE cells

Microcurrent stimulation promotes ion flow across the retinal pigment epithelium.

Step 3

Improves  regenerative and metabolic processes of RPE cells

By re-establishing electrical polarity across the RPE, the therapy is designed to support normal retinal electrophysiology.

Step 4

Improves electrophysiology of photoreceptors and other neural cells

Intended to support photoreceptor activity and retinal homeostasis.

Mechanistic Outcomes

Designed to support key retinal functions

Restored Electrical Polarity (TEP)

Improved Photoreceptor Response Time

Increased Protective Signaling (PEDF)

Enhanced Waste Clearance (Phagocytosis)

The i-LUMEN™ AMD System targets TEP restoration through non-invasive bioelectric stimulation.

See how it works
Clinical Trials

Early evidence. Measurable results.

The i-SIGHT study—a multicenter, randomized, controlled trial—is producing promising results and now enrolling across the US, UK, Australia, and New Zealand.

Learn more about the study

Week 2

3.4 ms

improvement in photoreceptor response

Month 3

9.6

letter mean improvement

Month 2

61.5%

achieved ≥10 letter gain

Tagline

Heading goes here

Lorem ipsum dolor sit amet, consectetur adipiscing elit.

For eye professionals

Discover the i-Lumen AMD System®

A non-invasive bioelectric therapy targeting retinal electrophysiology in dry AMD.

Learn more
for investors

Discover the opportunity

AMD is a leading cause of vision loss worldwide in adults over age 50, with prevalence expected to rise significantly over the next decade.

Learn more